Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVES:
I. To define the safety of gefitinib administered in conjunction with irradiation in children with newly diagnosed non-disseminated diffuse intrinsic brainstem gliomas and newly diagnosed incompletely resected supratentorial malignant gliomas (STMG) not receiving enzyme inducing anticonvulsant drugs (EIACDs).
II. To define the safety of gefitinib in children with newly diagnosed, incompletely resected STMG receiving EIACDs.
III. To assess the safety and efficacy of gefitinib given with radiation therapy in children newly diagnosed with a brainstem glioma as measured by progression-free survival and to estimate the survival distribution.
SECONDARY OBJECTIVES:
I. To compare hemodynamic magnetic resonance (MR) parameters to metabolic fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scanning and correlate both with clinical response or progression in this population.
II. To characterize the expression of ErbB1 receptors in tissue from STMG patients using immunohistochemistry and western blot assays.
III. To characterize the pharmacokinetics of gefitinib in the above patient groups and determine the effects of EIACD on the pharmacokinetics.
IV. To explore the pharmacogenetic polymorphisms for gefitinib (e.g., CYP3A4/5 and BCRP) and relate them to gefitinib pharmacokinetics and pharmacodynamics (phenotype-genotype).
OUTLINE: This is a multicenter, dose-escalation study of gefitinib (Phase I closed to accrual effective 10/27/2003). Patients are stratified according to the following:
Stratum 1A: Intrinsic brain stem glioma; not receiving concurrent enzyme-inducing anticonvulsant drugs (EIACDs) Stratum 1B: Incompletely resected supratentorial malignant gliomas (STMG); not receiving concurrent EIACDs Stratum 2: Incompletely resected STMG; receiving concurrent EIACDs.
Phase I portion (patients in strata 1A, 1B, and 2) (phase I closed to accrual effective 10/27/2003): Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Phase II portion (patients in stratum 1A): Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed brain stem gliomas (BSG) are treated at the MTD or the recommended Phase-II dose.
Patients are followed for three months after the last protocol treatment for those enrolled strictly on the phase I component. Patients contributing to the phase II portion are followed until the earliest of date of death or three years after initiation of protocol therapy.
PROJECTED ACCRUAL: Considering the seven dose levels to be investigated in three strata, where each dose level can accrue up to six patients, a total of 126 patients (42 for each strata) may be accrued for this study within 2 years. (Phase I closed to accrual effective 10/27/2003). A total of 40 patients including the patients treated at the maximum tolerated dose or the recommended Phase-II dose during Phase I will be accrued for phase II of this study within 10 months.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Tennessee
-
Memphis、Tennessee、美国、38105
- Pediatric Brain Tumor Consortium
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Tumor:
- Phase I: newly diagnosed non-disseminated diffuse intrinsic brainstem tumor or newly diagnosed (diagnostic scan must be within 4 weeks prior to treatment initiation), incompletely resected supratentorial malignant glioma (anaplastic astrocytoma, glioblastoma multiforme or other high-grade glioma) (STMG); the STMG group must have residual tumor evident on postoperative MRI or CT
- Phase II: only newly diagnosed non-disseminated diffuse intrinsic brain stem glioma patients are eligible
- Performance status: Karnofsky or Lansky >= 50% assessed within two weeks prior to registration
Prior/concurrent therapy:
- Chemotherapy: no prior therapy allowed, including prior gefitinib treatment
- Radiation therapy (XRT): no prior therapy allowed
- Bone marrow transplant: none prior
- Anti-convulsants: patients with brain stem glioma (BSG) receiving EIACD will not be eligible; patients with STMG will be eligible for this study even if they are receiving enzyme inducting anti-convulsant drugs (EIACD) and will be stratified by use of EIACDs
- Growth factors: off all colony forming growth factor(s) > 2 weeks prior to registration (G-CSF, GM-CSF, erythropoietin)
- ANC > 1,000/ul
- Platelets > 100,000/ul (transfusion independent)
- Hemoglobin > 8g/dl (may be transfused)
- Patients may have bone marrow involvement by disease
- Creatinine < 2 x normal for age or GFR > 70 ml/min/1.73m^2
- Bilirubin < 1.5 x normal institutional normal for age
- SGPT (ALT) < 3 x institutional normal for age
- Pregnant and/or lactating patients are excluded; patients of childbearing potential should not become pregnant and should not father a child during treatment with gefitinib; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- Signed informed consent according to institutional guidelines must be obtained prior to study entry
Exclusion Criteria:
- Patients with evidence of intramural hemorrhage on a scan obtained prior to enrollment or after enrollment, before treatment
- Patients with BSG must not be taking enzyme-inducing anticonvulsant drugs
- Patient must not be receiving any other anticancer or experimental drug therapy
- Patient must have no uncontrolled infection
- Patients with significant cardiac, hepatic, gastrointestinal, renal, pulmonary, or psychiatric disease are ineligible; patients with deep venous or arterial thrombosis within 6 weeks of study entry are ineligible
- Patients with disseminated disease are not permitted
- Patients with spinal disease requiring craniospinal radiation are not eligible
- Patients with completely resected supratentorial malignant gliomas patients are ineligible
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Treatment (gefitinib and radiation therapy)
Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity. Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose. |
相关研究
口头给予
其他名称:
相关研究
其他名称:
Undergo standard brain irradiation
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy
大体时间:Day 1 of gefitinib therapy to end of week 8
|
The dose limiting toxicity (DLT) analysis population consists of stratum 1A phase I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (course 1 and 2) or who completed the MTD estimation period without DLTs.
DLTs observed during courses 1 and 2 were used to estimate the MTD based on the tradional 3+3 design, where a dose is considered a safe dose only when 0 out of 3, or at most 1 out of 6 patients has DLTs.
When two or more patients in a group of 2 to 6 patients had DLTs, then that dose level was considered to be too toxic.
|
Day 1 of gefitinib therapy to end of week 8
|
Median Progression-free Survival in Newly Diagnosed Brain Stem Gliomas
大体时间:Assessed pre-radiation, every 8 weeks for 13 courses of therapy, and then every 12 weeks
|
Progression-free survival is defined as the interval from intiation of treatment to the earliest of disease progression (tumor increase of 25% over baseline tumor measurement; appearance of new lesion(s); or progressive/worsening neurlogical status) or death for patients who failed or to the last date of follow-up for patients without failure
|
Assessed pre-radiation, every 8 weeks for 13 courses of therapy, and then every 12 weeks
|
Median Survival in Newly Diagnosed Brain Stem Gliomas
大体时间:Assessed from the start of therapy until three years after initiation of gefitinib therapy
|
Overall survival is defined as the interval from initiation of treatment to death or date of last contact for surviving patients
|
Assessed from the start of therapy until three years after initiation of gefitinib therapy
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
基线时测量的平均肿瘤灰质比
大体时间:基线
|
本研究试图通过正电子发射断层扫描来表征神经影像学参数。
对于每位患者,通过肿瘤的轴向图像包含对应于最高氟脱氧葡萄糖 (FDG) 摄取的最大活性的每个像素,并根据肿瘤的 FDG 定义绘制感兴趣区域 (ROI)。
肿瘤 ROI 内的平均像素值通过正常灰质的平均像素值进行标准化,以提供肿瘤/灰质的比率。
每个患者都有一个平均肿瘤与灰质比率值,并报告了这些值在患者中的中值。
|
基线
|
Change in Tumor Volume Measured on Fluid Attenuated Inversion Recovery (FLAIR) Imaging at Before the Protocol Therapy Started and at Two Weeks After Completion of Radiation
大体时间:Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
In this particular objective, the study aimed to investigate how radiation+gefitinib affect the tumor volume.
Tumor volume is measured using Fluid Attenuated Inversion Recovery (FLAIR) before and after the radiation therapy.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Volume Enhancing at Two Weeks After Completion of Radiation
大体时间:Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response,survival, etc.).
Volume enhancing is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Diffusion Ratio at Two Weeks After Completion of Radiation
大体时间:Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response,survival, etc.).
Diffusion ratio is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Perfusion Ratio at Two Weeks After Completion of Radiation
大体时间:Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response,survival, etc.).
Perfusion ratio is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
|
Baseline and two weeks post completion of radiation
|
Mean Tumor to White Matter Ratio Measured at Baseline
大体时间:Baseline
|
This study attempts to characterize neuroimaging parameters from positron emission tomography.
For each patient, the axial image through the tumor containing the maximum activity per pixel corresponding to the highest FluoroDeoxyGlucose (FDG) uptake was identified and a region of interest (ROI) was drawn based on the FDG definition of the tumor.
The mean pixel values within the tumor ROI were normalized by those for normal white matter to provide ratios of tumor/gray matter.
Each patient has a mean tumor to white matter ratio value and the median of these values across patients is reported.
|
Baseline
|
Peak Serum Concentration of Gefitinib (Cmax)
大体时间:Week 2 of course 1
|
Week 2 of course 1
|
|
Elimination Half Life of Gefitinib (t1/2)
大体时间:Week 2 of course 1
|
Week 2 of course 1
|
|
Clearance of Gefitinib (Cl)
大体时间:Week 2 of course 1
|
Week 2 of course 1
|
|
Time of Maximum Clearance of Gefitinib (Tmax)
大体时间:Week 2 of course 1
|
Week 2 of course 1
|
|
Gefitinib Area Under the Concentration Curve From 0-24 Hours (AUC)
大体时间:Week 2 of course 1
|
Week 2 of course 1
|
|
Number of Patients With Epidermal Growth Factor Receptor (EGFR) Amplification
大体时间:Pre-treatment
|
Epidermal growth factor receptor (EFGR) is a protein found on the surface of cells to which epidermal growth factor (EGF) binds.
When EGF attaches to EGFR, it activates the enzyme tyrosine kinase, triggering reactions that cause the cells to grow and multiply.
|
Pre-treatment
|
合作者和调查者
调查人员
- 首席研究员:Jeffrey Geyer、Pediatric Brain Tumor Consortium
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NCI-2012-03022 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- U01CA081457 (美国 NIH 拨款/合同)
- PBTC-007 (其他标识符:CTEP)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
实验室生物标志物分析的临床试验
-
ORIOL BESTARD完全的
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)尚未招聘艾滋病毒感染 | 乙型肝炎
-
Hvidovre University HospitalElsassFonden终止
-
Fundació Sant Joan de DéuStanley Medical Research Institute; Parc Sanitari Sant Joan de Déu; Hospital Sant Joan de Deu完全的